Ad is loading...
PRME
Price
$3.35
Change
-$0.25 (-6.94%)
Updated
Nov 15 closing price
RIGL
Price
$24.10
Change
-$3.36 (-12.24%)
Updated
Nov 15 closing price
Ad is loading...

PRME vs RIGL

Header iconPRME vs RIGL Comparison
Open Charts PRME vs RIGLBanner chart's image
Prime Medicine
Price$3.35
Change-$0.25 (-6.94%)
Volume$1.4M
CapitalizationN/A
Rigel Pharmaceuticals
Price$24.10
Change-$3.36 (-12.24%)
Volume$398.28K
CapitalizationN/A
PRME vs RIGL Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
PRME vs. RIGL commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a StrongSell and RIGL is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (PRME: $3.35 vs. RIGL: $24.10)
Brand notoriety: PRME and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 77% vs. RIGL: 179%
Market capitalization -- PRME: $438.73M vs. RIGL: $424.52M
PRME [@Biotechnology] is valued at $438.73M. RIGL’s [@Biotechnology] market capitalization is $424.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, RIGL is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 5 bullish TA indicator(s).

  • PRME’s TA Score: 4 bullish, 5 bearish.
  • RIGL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than PRME.

Price Growth

PRME (@Biotechnology) experienced а -18.41% price change this week, while RIGL (@Biotechnology) price change was +9.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

PRME is expected to report earnings on Nov 13, 2024.

RIGL is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($439M) and RIGL($425M) have the same market capitalization . RIGL YTD gains are higher at: 66.207 vs. PRME (-62.246). RIGL has higher annual earnings (EBITDA): -4.93M vs. PRME (-204.68M). PRME has more cash in the bank: 163M vs. RIGL (49.1M). PRME has less debt than RIGL: PRME (41.6M) vs RIGL (60.3M). RIGL has higher revenues than PRME: RIGL (130M) vs PRME (591K).
PRMERIGLPRME / RIGL
Capitalization439M425M103%
EBITDA-204.68M-4.93M4,156%
Gain YTD-62.24666.207-94%
P/E RatioN/A89.26-
Revenue591K130M0%
Total Cash163M49.1M332%
Total Debt41.6M60.3M69%
FUNDAMENTALS RATINGS
PRME vs RIGL: Fundamental Ratings
PRME
RIGL
OUTLOOK RATING
1..100
7048
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
89
Overvalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8934
P/E GROWTH RATING
1..100
10078
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (73) in the null industry is in the same range as RIGL (89) in the Biotechnology industry. This means that PRME’s stock grew similarly to RIGL’s over the last 12 months.

RIGL's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that RIGL’s stock grew similarly to PRME’s over the last 12 months.

RIGL's SMR Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that RIGL’s stock grew similarly to PRME’s over the last 12 months.

RIGL's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for PRME (89) in the null industry. This means that RIGL’s stock grew somewhat faster than PRME’s over the last 12 months.

RIGL's P/E Growth Rating (78) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that RIGL’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMERIGL
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 18 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
65%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSFEX15.230.04
+0.26%
Morgan Stanley Inst Next Gen Em Mkts C
BFGUX46.02-0.35
-0.75%
Baron Focused Growth R6
GTENX46.26-0.39
-0.84%
Gateway N
MSPRX19.35-0.20
-1.02%
Morgan Stanley Inst Advantage C
JFACX37.75-0.56
-1.46%
JHancock Fundamental All Cap Core R2

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-6.95%
BEAM - PRME
61%
Loosely correlated
-8.59%
NTLA - PRME
61%
Loosely correlated
-7.61%
CRSP - PRME
60%
Loosely correlated
+0.85%
ABCL - PRME
57%
Loosely correlated
-3.99%
RXRX - PRME
55%
Loosely correlated
-10.64%
More

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with ALLO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
-12.24%
ALLO - RIGL
43%
Loosely correlated
-7.72%
KOD - RIGL
41%
Loosely correlated
+4.34%
RCUS - RIGL
41%
Loosely correlated
-0.44%
PRME - RIGL
40%
Loosely correlated
-6.95%
NTLA - RIGL
39%
Loosely correlated
-7.61%
More